Finch Therapeutics, Takeda expand collaboration to develop microbiome therapeutics
Under the terms of the expanded agreement, Finch and Takeda will utilize Finch’s platform to target Crohn’s disease, a form of inflammatory bowel disease. Finch’s Human-First Discovery platform